Asset Details
Do you wish to reserve the book?
Minorities Face Delays to Pancreatic Cancer Treatment Regardless of Diagnosis Setting
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Minorities Face Delays to Pancreatic Cancer Treatment Regardless of Diagnosis Setting
Do you wish to request the book?
Minorities Face Delays to Pancreatic Cancer Treatment Regardless of Diagnosis Setting
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Minorities Face Delays to Pancreatic Cancer Treatment Regardless of Diagnosis Setting
2024
Overview
Introduction
Our analysis was designed to characterize the demographics and disparities between the diagnosis of pancreas cancer during emergency presentation (EP) and the outpatient setting (OP) and to see the impact of our institutions pancreatic multidisciplinary clinic (PMDC) on these disparities.
Methods
Institutional review board-approved retrospective review of our institutional cancer registry and PMDC databases identified patients diagnosed/treated for pancreatic ductal adenocarcinoma between 2014 and 2022. Chi-square tests were used for categorical variables, and one-way ANOVA with a Bonferroni correction was used for continuous variables. Statistical significance was set at
p
< 0.05.
Results
A total of 286 patients met inclusion criteria. Eighty-nine patients (31.1%) were underrepresented minorities (URM). Fifty-seven (64.0%) URMs presented during an EP versus 100 (50.8%) non-URMs (
p
= 0.037). Forty-one (46.1%) URMs were reviewed at PMDC versus 71 (36.0%) non-URMs (
p
= 0.10). No differences in clinical and pathologic stage between the cohorts (
p
= 0.28) were present. URMs took 22 days longer on average to receive treatment (66.5 days vs. 44.8 days,
p
= 0.003) in the EP cohort and 18 days longer in OP cohort (58.0 days vs. 40.5 days,
p
< 0.001) compared with non-URMs. Pancreatic Multidisciplinary Clinic enrollment in EP cohort eliminated the difference in time to treatment between cohorts (48.3 days vs. 37.0 days;
p
= 0.151).
Results
Underrepresented minorities were more likely to be diagnosed via EP and showed delayed times to treatment compared with non-URM counterparts. Our PMDC alleviated some of these observed disparities. Future studies are required to elucidate the specific factors that resulted in these findings and to identify solutions.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Aged
/ Cancer
/ Carcinoma, Pancreatic Ductal - diagnosis
/ Carcinoma, Pancreatic Ductal - therapy
/ Female
/ Healthcare Disparities - statistics & numerical data
/ Humans
/ Male
/ Medicine
/ Minority Groups - statistics & numerical data
/ Oncology
/ Pancreatic Neoplasms - diagnosis
/ Pancreatic Neoplasms - therapy
/ Patients
/ Surgery
